Vaxart appoints Julie M. Cherrington, Ph.D. to Board of Directors

Vaxart, Inc.

Dr. Cherrington appointed to Vaxart's Board and Audit Committee effective August 20, 2021.
She receives annual cash retainers: $40k for Board, $7.5k for Audit Committee, plus time-based stock option for 65,700 shares vesting over 3 years.
Dr. Cherrington is CEO of QUE Oncology, has held leadership roles at Gilead, SUGEN, and several oncology biotechs.
Vaxart is developing oral tablet vaccines for COVID-19 and norovirus; Phase II COVID-19 trials expected.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Julie M. Cherrington

Director

VXRT · Vaxart, Inc.

Effective: 2021-08-20
Filed: August 23, 2021, 7:59 PM ET

On August 20, 2021, the Board of Directors (the “ Board ”) of Vaxart, Inc. (the “ Company ”) appointed Julie M. Cherrington, Ph.D., to serve on our Board until her successor is elected and qualified, or sooner in the event of her death, resignation, or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Julie M. Cherrington was appointed as Director at Vaxart, Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 20, 2021, the Board of Directors (the “ Board ”) of Vaxart, Inc. (the “ Company ”) appointed Julie M. Cherrington, Ph.D., to serve on our Board until her successor is elected and qualified, or sooner in the event of her death, resignation, or removal.

View on SEC.gov

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-21-020715

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.